161 related articles for article (PubMed ID: 38558740)
21. Using multi-criteria decision analysis to appraise orphan drugs: a systematic review.
Friedmann C; Levy P; Hensel P; Hiligsmann M
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):135-146. PubMed ID: 29210308
[TBL] [Abstract][Full Text] [Related]
22. Developing a Multi-Criteria Decision Analysis Tool to Support the Adoption of Evidence-Based Child Maltreatment Prevention Programs.
Cruden G; Frerichs L; Powell BJ; Lanier P; Brown CH; Lich KH
Prev Sci; 2020 Nov; 21(8):1059-1064. PubMed ID: 33040271
[TBL] [Abstract][Full Text] [Related]
23. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.
Roldán ÚB; Badia X; Marcos-Rodríguez JA; de la Cruz-Merino L; Gómez-González J; Melcón-de Dios A; Caraballo-Camacho MO; Cordero-Ramos J; Alvarado-Fernández MD; Galiana-Auchel JM; Calleja-Hernández MÁ
Int J Technol Assess Health Care; 2018 Jan; 34(5):519-526. PubMed ID: 30348241
[TBL] [Abstract][Full Text] [Related]
24. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
[TBL] [Abstract][Full Text] [Related]
25. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.
Blonda A; Denier Y; Huys I; Kawalec P; Simoens S
Front Pharmacol; 2022; 13():902150. PubMed ID: 35928274
[No Abstract] [Full Text] [Related]
26. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar P; Geirnaert M; Gavura S; Beca J; Mercer RE; Denburg A; Muñoz C; Tadrous M; Parmar A; Dionne F; Boehm D; Chambers C; Craig E; Trudeau M; Cheung MC; Houlihan J; McDonald V; Pechlivanoglou P; Taylor M; Wasylenko E; Wranik WD; Chan KKW
Curr Oncol; 2024 Apr; 31(4):1876-1898. PubMed ID: 38668044
[TBL] [Abstract][Full Text] [Related]
27. Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia.
Vandewalle B; Amorim M; Ramos D; Azevedo S; Alves I; Francisco T; Pinto H; Sousa S
Curr Med Res Opin; 2021 Jun; 37(6):1021-1030. PubMed ID: 33733971
[TBL] [Abstract][Full Text] [Related]
28. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
Angelis A; Kanavos P
Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
[TBL] [Abstract][Full Text] [Related]
29. The challenge of obtaining information necessary for multi-criteria decision analysis implementation: the case of physiotherapy services in Canada.
Dionne F; Mitton C; Macdonald T; Miller C; Brennan M
Cost Eff Resour Alloc; 2013 May; 11(1):11. PubMed ID: 23688138
[TBL] [Abstract][Full Text] [Related]
30. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
31. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
Kwon SH; Park SK; Byun JH; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
[TBL] [Abstract][Full Text] [Related]
32. Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand.
Holtorf AP; Kristin E; Assamawakin A; Upakdee N; Indrianti R; Apinchonbancha N
J Pharm Policy Pract; 2021 Jun; 14(1):52. PubMed ID: 34127071
[TBL] [Abstract][Full Text] [Related]
33. Guidance toward the implementation of multicriteria decision analysis framework in developing countries.
Inotai A; Nguyen HT; Hidayat B; Nurgozhin T; Kiet PHT; Campbell JD; Németh B; Maniadakis N; Brixner D; Wijaya K; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):585-592. PubMed ID: 30092151
[TBL] [Abstract][Full Text] [Related]
34. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Jiménez A; Ais A; Beaudet A; Gil A
Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
[TBL] [Abstract][Full Text] [Related]
35. Multi-criteria decision analysis of breast cancer control in low- and middle- income countries: development of a rating tool for policy makers.
Venhorst K; Zelle SG; Tromp N; Lauer JA
Cost Eff Resour Alloc; 2014; 12():13. PubMed ID: 24855456
[TBL] [Abstract][Full Text] [Related]
36. Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.
Mühlbacher AC; Kaczynski A
Appl Health Econ Health Policy; 2016 Feb; 14(1):29-40. PubMed ID: 26519081
[TBL] [Abstract][Full Text] [Related]
37. Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development.
Kremer IEH; Jongen PJ; Evers SMAA; Hoogervorst ELJ; Verhagen WIM; Hiligsmann M
BMC Med Inform Decis Mak; 2021 Apr; 21(1):123. PubMed ID: 33836742
[TBL] [Abstract][Full Text] [Related]
38. Methods and criteria for the assessment of orphan drugs: a scoping review.
Mohammadshahi M; Olyaeemanesh A; Ehsani-Chimeh E; Mobinizadeh M; Fakoorfard Z; Akbari Sari A; Aghighi M
Int J Technol Assess Health Care; 2022 Jun; 38(1):e59. PubMed ID: 35730573
[TBL] [Abstract][Full Text] [Related]
39. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
Iskrov GG; Raycheva RD; Stefanov RS
Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
[TBL] [Abstract][Full Text] [Related]
40. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
